Finch Therapeutics Group, Inc. (FNCH)

2.1200 -0.0600 (-2.75%) At close: 04:00PM EDT

Finch Therapeutics Group, Inc.

75 State Street
Suite 100
Boston, MA 02109
United States
617 229 6499
https://www.finchtherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Matthew P. Blischak J.D.	President, Secretary & CEO	558.81k	N/A	1963
Mr. Lance Thibault CPA	Chief Financial Officer	168.79k	N/A	1966
Mr. James S. Sigler MBA	Executive Vice President of CMC	N/A	N/A	1961

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Corporate Governance

Finch Therapeutics Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.